Journal of the National Cancer Institute · 2011
Twelfth biannual report of the Cochrane Haematological Malignancies Group--focus on tyrosine kinase inhibitors.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Skoetz Nicole, Kluge Sabine, Monsef Ina, Bauer Kathrin, Siebert Hendrik, Kreuzer Karl-Anton, Engert Andreas
Аннотация
This 12th biannual report of the Cochrane Haematological Malignancies Group highlights recently published randomized controlled trials in the field of hemato-oncology, covering the publication period from September 1, 2009, through June 30, 2010. Implication for clinical practice and methodological aspects are the main principles used to select trials for this report. Studies on tyrosine kinase inhibitors for patients with chronic myeloid leukemia were identified through electronic search of MEDLINE with a broad search filter that covered all topics in hemato-oncology combined with a highly sensitive search filter for randomized studies as described in the Cochrane Handbook for Systematic Reviews of Interventions.
Предметные рубрики MeSH
Adrenal Cortex HormonesAminoglycosidesAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, Monoclonal, Murine-DerivedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBenzamidesCyclophosphamideDasatinibDiphosphonatesDisease-Free SurvivalEpoetin AlfaErythropoietinEvidence-Based MedicineGemtuzumabGraft vs Host DiseaseHematologic NeoplasmsHodgkin DiseaseHumansImatinib MesylateInterferon-alphaLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMethotrexatePiperazinesProtein Kinase InhibitorsProtein-Tyrosine KinasesPyrimidinesRandomized Controlled Trials as TopicRecombinant ProteinsRituximabStem Cell TransplantationThiazolesTreatment OutcomeVidarabine